What is that doing?

CRISPR-GBT is like any AI system.

We have AI system that help you write your email or help you summarize a book.

What we found that even though CRISPR itself is very low cost, very fast today, what is really hard and expensive is actually before and after.

Before meaning, for example, I'm studying cancer, which is actually one of our collaboration project.

And what they want to do is to specifically target some of the genes that are mutated in lung cancer patients.

But then the problem is there are many genes, right? And every gene in the human genome has over sometimes 30,000 bases.

And that could be a pretty big deal, especially when it comes to medicine.

Mm-hmm.

Uh, very powerful.

We know that, um, essentially it recombines two piece of DNA.

And if a patient is missing, um, a key gene or have a mutation that inactivated the gene, if we can use, um, a recombinase, right, to essentially recombine a donor DNA into the genome, then you can give the patient or give the target cell a fresh, correct, new copy of a gene, uh, as sort of a, you know, cure almost, right, for any, you know, errors or loss of function, um, in genetic diseases.

So we really thought, what if we have a Cre that can be targeted to anywhere in the genome versus classically, as we all know, Cre recombinase have a single sequence that it will work.

So only that sequence.

Of course, can, can be engineered a little bit, but essentially it's a very single site recombination protein.

[laughs]